[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains

doi:10.1021/jm401568s

Paper

[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains

Published Dec 8, 2013 · O. Fedorov, Hannah Lingard, C. Wells

Journal of Medicinal Chemistry

Q1 SJR score

80

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Bromodomains are gaining increasing interest as drug targets. Commercially sourced and de novo synthesized substituted [1,2,4]triazolo[4,3-a]phthalazines are potent inhibitors of both the BET bromodomains such as BRD4 as well as bromodomains outside the BET family such as BRD9, CECR2, and CREBBP. This new series of compounds is the first example of submicromolar inhibitors of bromodomains outside the BET subfamily. Representative compounds are active in cells exhibiting potent cellular inhibition activity in a FRAP model of CREBBP and chromatin association. The compounds described are valuable starting points for discovery of selective bromodomain inhibitors and inhibitors with mixed bromodomain pharmacology.

Highly Cited

Study Snapshot

Submicromolar inhibitors of [1,2,4]triazolo[4,3-a]phthalazines effectively inhibit diverse bromodomains, offering potential for selective and mixed bromodomain inhibitors.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains

Sign up to use Study Snapshot

References

Citations